A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have received EU approval and have launched in the crowded MS market. Given the rapid pace of change in the MS market, developers of both current and emerging DMTs must continually reassess their products’ differentiation and likely positioning in this highly competitive space. This report will explore neurologists’ perceptions of established and newly launched DMTs, their prescribing habits in today’s market, and anticipated changes in brand usage as more DMTs expand—and further complicate—prescriber choice.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets Covered: France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Survey of 50 neurologists in France, Germany, Italy, Spain, and the United Kingdom.
Key drugs covered: Aubagio, glatiramer acetate, Gilenya, Interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera, Tysabri, Zeposia, Vumerity
Key companies: Biogen, Bristol Myers Squibb, Janssen, Merck KGaA, Novartis, Roche, Sanofi Genzyme, Teva, Viatris
Key insights provided: